Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma

Table 1 Clinical characteristics of the 81 patients, n (%)

Characteristics	Patients, n = 81
Gender
Male	59 (72.8)
Female	22 (27.2)
Smoking status
Nonsmoker	39 (48.1)
Former or current smoker	42 (51.9)
Pathological type
Adenocarcinoma	62 (76.5)
Squamous cell carcinoma	11 (13.6)
Adenosquamous carcinoma	3 (3.7)
NSCLC-NOS	5 (6.2)
Clinical stage
IIIA	15 (18.5)
IIIB	28 (34.6)
IIIC	3 (3.7)
IV	35 (43.2)
Distant metastasis
Malignant pleural effusion	3 (3.7)
Pleura	4 (4.9)
Contralateral lung	9 (11.1)
Bone	14 (17.3)
Brain	9 (11.1)
Liver	3 (3.7)
Adrenal gland	5 (6.2)

NSCLC-NOS: Non-small cell lung carcinoma-not otherwise specified.

Table 2 Puncture site and lesion size

Location of sample	Patients, n	Minimum, mm	Maximum, mm
Primary tumor
Right	18	24	65
Left	7	28	91
Lymph node
2R	2	10	21
4R	19	9	34
4L	4	27	28
5	2	19	38
7	35	15	70
8	2	12	20
10R	5	24	26
10L	3	23	45

2R: Right upper paratracheal; 4R: Right lower paratracheal; 4L: Left lower paratracheal; 5: Subaortic; 7: Subcarinal; 8: Paraesophageal; 10R: Right hilar; 10L: Left hilar.

Table 3 Puncture of multiple lesions

Location of sample	Patients, n
4R, 4L, 7	1
4R, 7	7
5, 7	1
7, 8	1
Left lung mass, 7	1
Right lung mass, 4R	2
Right lung mass, 7	2

4R: Right lower paratracheal; 4L: Left lower paratracheal; 5: Subaortic; 7: Subcarinal; 8: Paraesophageal.

Table 4 Molecular analysis of all patients

	Adenocarcinoma, n = 62	Squamous cell carcinoma, n = 11	Adenosquamous carcinoma, n = 3	NSCLC-NOS, n = 5
EGFR mutation
Exon 19
E746-A750del (1)	2	0	0	0
E746-A750del (2)	4	0	0	0
L747-T751del	2	0	0	0
L747-S752del	1	0	0	0
L747-A750del	1	0	0	0
Exon 21			0
L858R	8	0	1	0
L861Q	2	0	0	0
KRAS mutation
Exon 2
G12C	3	1	0	0
G12D	2	0	0	0
G12V	2	0	0	0
G12L	1	0	0	0
ROS-1 (FISH) positive	1	0	0	0
ALK (Ventana IHC) positive	5	0	0	0

NSCLC-NOS: Non-small cell lung carcinoma-not otherwise specified; ALK: Anaplastic lymphoma kinase; FISH: Fluorescence in situ hybridization; IHC: Immunohistochemistry.

Table 5 Molecular analysis of patients with multiple lesions

	Type	Puncture site	Mutation	Puncture site	Mutation
1	Adenocarcinoma	5	Insufficient sample	7	EGFR, exon 21 L858R
2	Adenocarcinoma	Right lung mass	EGFR, exon 21 L858R	7	EGFR, exon 21 L858R
3	Adenocarcinoma	4R	EGFR, exon 21 L858R	7	EGFR, exon 21 L858R
4	Squamous cell carcinoma	4R	KRAS, exon 2 G12C	7	KRAS, exon 2 G12C

4R: Right lower paratracheal; 5: Subaortic; 7: Subcarinal.

Table 6 Response to targeted therapy

	Drugs	CR, n	PR, n	SD, n	PD, n
EGFR mutation	Gefitinib, erlotinib, extinib	0	13	3	3
ROS-1 positive	Crizotinib	0	0	1	0
ALK positive	Crizotinib	0	3	0	1

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.